{"url_path":"/fda/drug/recalls/D-0727-2026","section_key":"summary","section_title":"DRUG Recall: Fresenius Kabi USA, LLC — Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial:  63323-286-05","topic":"fda","document":{"doc_type":"drug-recall","doc_date":"2026-07-16","source_url":"https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0727-2026%22","accession_number":null,"cik":null,"ticker":null,"issuer_name":null,"edgar_url":null,"primary_entity_key":null,"primary_entity_name":"Fresenius Kabi USA, LLC"},"word_count":88,"has_tables":false,"body_markdown":null}